ClinicalTrials.gg
CompletedNCT04570267Updated Oct 4, 2022

Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects

A Phase 1 interventional study of CSL324 and Placebo in Healthy, sponsored by CSL Behring. Completed at 1 site in Australia. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by CSL Behring (part of CSL Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

Study CSL324_1003 is a single center, randomized, double-blind, placebo-controlled study designed to characterize and compare the PK properties and safety of a single subcutaneous dose of CSL324 in healthy Japanese and White subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.

First submitted after CSL Behring became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female Japanese or White subjects aged 20 and 55 years, inclusive
  • Body weight of at least 45 kg to 100 kg, inclusive
  • of 18.0 to 32.0 kg/m2, inclusive

Exclusion criteria

Exclusion Criteria:

  • A medical condition, disorder, or disease of any organ system.
  • Concurrent diagnosis of or history of malignancy (except for nonmelanoma skin cancer or cervical carcinoma in situ that has been adequately treated with no evidence of recurrence for at least 3 months before Screening).
  • conditions and / or currently taking immunosuppressive or immunomodulative therapy.
  • Clinically significant abnormalities on physical examination, vital signs, or laboratory assessments, or neutropenia (defined as \< 2.0 × 109/L).
  • History of chronic or recurrent infections, clinical signs of active infection and / or fever, current / history of serious infection or hospitalized or received IV antibiotics for an infection in previous 2 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    CSL324 (Low dose)

    One low dose of CSL324 administered subcutaneously on Day 1

    Biological: CSL324

  • Experimental
    CSL324 (High dose)

    One high dose of CSL324 administered subcutaneously on Day 1

    Biological: CSL324

  • Placebo comparator
    Placebo

    One dose of placebo administered subcutaneously on Day 1

    Drug: Placebo

Interventions

  • BiologicalCSL324

    Sterile solution of recombinant anti G-CSF receptor monoclonal antibody for injection

    Also known as: Recombinant Anti G-CSF Receptor Monoclonal Antibody

  • DrugPlacebo

    Sterile solution of CSL324 formulation buffer for injection

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax) of CSL324 in serum

    Time frame: From Day 1 to Day 56

  2. Area under the concentration-time curve from time 0 extrapolated to time infinity (AUC0-inf) of CSL324 in serum

    Time frame: From Day 1 to Day 56

  3. Area under the concentration-time curve from time 0 to the last measurable concentration (AUC0-last) of CSL324 in serum

    Time frame: From Day 1 to Day 56

Secondary outcomes

  1. Number of subjects with treatment-emergent adverse events (TEAEs) by incidence, by severity, and by causality

    Time frame: Up to Day 56

  2. Percentage of subjects with TEAEs by incidence, by severity, and by causality

    Time frame: Up to Day 56

  3. Number of subjects with adverse events localized to the administration site by incidence, by severity, and by causality

    Time frame: Up to Day 7

  4. Percentage of subjects with adverse events localized to the administration site by incidence, by severity, and by causality

    Time frame: Up to Day 7

  5. Time to reach Cmax (Tmax) for CSL324 in serum

    Time frame: From Day 1 to Day 56

  6. Terminal half-life (t1/2) for CSL324 in serum

    Time frame: From Day 1 to Day 56

  7. Apparent clearance (CL/F) for CSL324 in serum

    Time frame: From Day 1 to Day 56

  8. Apparent volume of distribution (Vz/F) for CSL324 in serum

    Time frame: From Day 1 to Day 56

  9. Number of subjects with or without anti-CSL324 antibodies

    Time frame: Up to Day 56

  10. Percentage of subjects with or without anti-CSL324 antibodies

    Time frame: Up to Day 56

07

Study locations

1 site
  • Scientia Clinical Research Ltd
    Randwick, Australia
08

References and documents

Individual participant data

Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting information: Study protocol, Statistical analysis plan

Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.

Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Nov 2021, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2020
First posted
Sep 30, 2020
StartActual
Oct 8, 2020
Primary completionActual
Nov 17, 2021
CompletionActual
Dec 9, 2021
Last update
Oct 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04570267
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Sep 30, 2020
Start date
Oct 8, 2020
Primary completion
Nov 17, 2021
Completion
Dec 9, 2021
Last update
Oct 4, 2022

Study contacts

Study Director
study director · CSL Behring

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anumigilimab

Start the discussion